Figure S3 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Recurrence-free survival and overall survival by adjuvant chemotherapy use in RCB II/III patients</p

Figure S2 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Recurrence-free survival and overall survival in the overall patient population</p

Figure S1 from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Pathological response to carboplatin plus docetaxel by germline BRCA status</p

Supplementary Methods and Results from Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Further description of patient population and exploratory analysis.</p